Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Q3 FY26 Earnings Presentation
21 slides from Alivus Life Sciences's earnings presentation, Jan 22, 2026
Slide 1: Exchange filing cover letter for Investor Presentation
January 22, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322
Slide 2: Investor Presentation Q3FY26
Investor Presentation Q3FY26
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Financial Performance Review
Financial Performance Review 3
Slide 5: Q3FY26 Highlights
Q3FY26 | Highlights “This quarter showed a clear improvement in our operating performance. The CDMO business recovered as expected, delivering the turnaround we had planned for in the second half of the year. We also saw robust growth in Non-GPL business especially across our key markets, including
Slide 6: Q3 & 9M FY26 Performance
Q3 & 9M FY26 Performance Revenue EBITDA PAT EPS (In ₹ Mill i on ) (In ₹ Mill i on ) (In ₹ Mill i on ) (In ₹) 33.0% 36.4% 21.3% 21.8% 22.1% 22.3% 32.1% 30.1% 20.2% 31.3% 6,729 1,419 12.25 1,370 1,503 2,452 11.57 6,496 1,301 6,418 11.18 1,215 10.60 2,085 9.91 2,008 6,018 1,939 5,880 1,813 Q3FY25 Q4FY2
Slide 7: P&L Highlights | Q3 & 9M FY26
P&L Highlights | Q3 & 9M FY26 Particulars (In ₹ Million) Q3 FY26 Q2 FY26 QoQ Q3 FY25 YoY 9M FY26 9M FY25 YoY FY25 Revenue from Operations 6,729 5,880 14.4% 6,418 4.8% 18,627 17,373 7.2% 23,869 Gross Profit 3,965 3,391 16.9% 3,566 11.2% 10,671 9,391 13.6% 13,061 Gross Profit (%) 58.9% 57.7% +120 bps
Slide 8: Healthy Return Indicators
Healthy Return Indicators ROICE (%) Fixed Assets Turnover (Times) 40% 34% 3.4 32% 31% 2.9 2.7 27% 2.5 2.3 FY22 FY23 FY24 FY25 9MFY26 FY22 FY23 FY24 FY25 9MFY26 • ROICE is tracking at ~31% – Capital employed driven by calibrated capex strategy and better margins • FATR is 2.3 times – Asset turn trend
Slide 9: Robust Growth & Steady Profitability
Robust Growth & Steady Profitability Revenue EBITDA PAT EPS (In ₹ Mil l ion ) (In ₹ Mill i on ) (In ₹ Mill i on ) (In ₹) EBITDA Margin PAT Margin 31.5% 31.4% 31.1% 21.6% 30.1% 30.0% 20.6% 20.3% 19.7% 39.63 38.43 38.11 7,172 4,857 6,863 23,869 4,709 6,712 35.63 4,670 18.6% 22,832 6,308 32.62 21,612 2
Slide 10: Business Performance Review
Business Performance Review 9
Slide 11: Segmental Performance | Generic API vs CDMO
Segmental Performance | Generic API vs CDMO Generic API CDMO (Revenu e In ₹ Milli o n ) (Revenu e In ₹ Milli o n ) 556 5,966 5,941 6,070 434 5,513 5,464 364 300 278 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 • Generic API revenues in Q3FY26 grew by 11.1% • CDMO business sa
Slide 12: Segmental Performance | GPL vs Non-GPL
Segmental Performance | GPL vs Non-GPL GPL % of Total Revenue Non-GPL % of Total Revenue (In ₹ Mill i on ) (In ₹ Mill i on ) 33.6% 72.4% 75.6% 30.0% 74.6% 4,645 4,711 27.6% 25.4% 4,443 2,181 24.4% 4,315 4,492 1,773 2,018 1,526 1,437 70.0% 66.4% Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q3FY25 Q4FY25 Q1FY26
Slide 13: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Mix 18% 14% 17% 19% 17% 30% 30% 31% 34% 39% Emerging Acute Markets 82% 86% 83% 81% 83% Chronic 70% 70% 69% 66% Regulated 61% Markets Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 • Regulated markets contributed 83% in Q3F
Slide 14: Company Overview
LIFE SCIENCES Company Overview ¢
Slide 15: Global Footprint
Global Footprint • Filed 595 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 370+ 30+ 156 180 70+ 10+ 116 21 125+ 595 50+ 10+ DMFs and 98 24 (Brazil) CEPs 14 Regulated Emerging India - Mix of Regulated Number of C
Slide 16: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend (In ₹ Mill i on ) North Therapy Europe Japan Brazil Australia ROW Total % of Total Revenue America CVS 39 40 4 27 11 41 162 CNS 43 26 8 18 3 21 119 Anti-Infective 21 11 3 3 3 14 55 3.5% Diabetes 10 5 - 9 1 17 42 3.4% 3.3% Dermatology 9 6 1 13 1 11
Slide 17: Quality Focused Manufacturing and R&D Infrastructure
Quality Focused Manufacturing and R&D Infrastructure Manufacturing Infrastructure R&D Infrastructure* Annual Installed Last USFDA Location Approvals Mahape, Navi Mumbai Capacity Inspection Date USFDA, MHRA (UK), FIMEA ▪ R&D for new product (Finland), Romania (Europe) PMDA development and complex Ank
Slide 18: Strategy Going Forward
LIFE SCIENCES Strategy Going Forward ¢
Slide 19: Strategy Growth Levers
Strategy Growth Levers 1 Gx API Business ✓ New product launches New Growth levers 2 ✓ Geographical expansion ✓ Focus on new markets becoming more regulated ✓ CDMO Ramp up ✓ Pursue 2nd source opportunities with top generic players ✓ Expand into complex API platforms ✓ Iron compounds ✓ Oncology & HP A
Slide 20: Future Capacity Expansion
Future Capacity Expansion Operational Expansion Type Division Location Status & Planned Capacity Timelines Brownfield API / Intermediate Ankleshwar Planned addition of ~100KL Capacity Q2 FY27 Brownfield API Dahej Planned addition of ~160KL Capacity Q2 FY27 Phase 1 – ~115 KL (API and intermediate blo
Slide 21: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@alivus.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RUNJHUN JAIN SNEHA SALIAN Email: diwakar.pingle@in.ey.com Email: runjhun.jain1@in.ey.com Email: sneha2.salian@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68